Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Challenges of nmCRPC management: to treat or not?

Robert Jones • 18 Jan 2019
ESMO 2018
Genitourinary Cancer Prostate Cancer

Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the challenges surrounding the management of non-metastatic castration-resistant prostate cancer (nmCRPC). Prof. Jones reflects on current trials demonstrating a delay in the onset of metastatic disease, and whether this is a meaningful and preferred endpoint. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Robert Jones

Areas of unmet need in metastatic urothelial carcinoma
2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
ASCO 2022: genitourinary cancer highlights
1:10
ASCO 2022: genitourinary cancer highlights
Robert Jones • 4 Jun 2022
Replacing the current standard of care for urothelial carcinoma
0:58
Replacing the current standard of care for urothelial carcinoma
Robert Jones • 4 Jun 2022
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals